Harvard Bioscience (HBIO) Set to Announce Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) is set to release its earnings data on Tuesday, April 23rd.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%. The company had revenue of $28.15 million for the quarter, compared to the consensus estimate of $27.80 million.

Harvard Bioscience Trading Down 6.8 %

NASDAQ HBIO opened at $3.70 on Monday. Harvard Bioscience has a 1-year low of $3.69 and a 1-year high of $6.29. The stock has a 50-day moving average of $4.32 and a 200-day moving average of $4.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.85 and a quick ratio of 0.92.

Institutional Trading of Harvard Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC raised its stake in Harvard Bioscience by 230.5% in the first quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 4,966 shares in the last quarter. Barclays PLC bought a new stake in shares of Harvard Bioscience in the second quarter worth approximately $43,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Harvard Bioscience by 47.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 3,200 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $37,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Harvard Bioscience during the 2nd quarter valued at $61,000. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.